The antibody transfer agreement between Shengshi Junlian and Sesselqing went smoothly and achieved milestone results

On August 1, 2023 in Chengdu, China, Chengdu Shengshi Junlian Biotechnology Co., Ltd. (hereinafter referred to as "Shengshi Junlian") announced that it has entered into an An antibody transfer agreement achieves first milestone.

In February 2023, Shengshi Junlian and Sesselqing reached an antibody transfer agreement. According to the agreement, after rigorous experimental verification, Sasselqing confirmed that the antibody met the requirements of the agreement, and paid the first transfer fee to Shengshi Junlian in July 2023. The transferred antibody comes from the antibody discovery platform independently constructed by Shengshi Junlian, which contains a "300 billion-level diversity" real biological drug library. With the smooth progress of the project, Shengshi Junlian may receive milestone payments in the clinical stage.